Primary DysmenorrheaPhase 3ASTRALNCT05640232
Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea
A Phase 3 study testing CDE100 association and Buscopan® Composto association in people with Primary Dysmenorrhea, run by EMS at 1 site in Brazil.
Trial summary
The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea. Read more about this study
- Who is it for?
- Ages 16 to 35 years, women only
- Conditions the study is for
- Primary Dysmenorrhea
- What is being tested?
- CDE100 association and Buscopan® Composto association
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 238 participants
- Where
- 1 siteBrazil
- Study dates
- 11 Jun 2025to 30 Jan 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 35 years
- Women only
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patient has given written informed consent to participate in the study prior to admission to the study;
- Female patients aged between 16 and 35 years old, inclusive;
- History of regular menstrual cycles, occuring between every 21 to 35 days;
- Clinical history compatible with the diagnosis of primary dysmenorrhea;
- Self-reported history of ≥ 4 painful cycles, with moderate or severe menstrual cramps, in the six (06) months prior to selection for the study.
Who cannot join
- Diagnosis of secondary dysmenorrhea;
- History of non-response to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) to relieve menstrual cramps;
- Onset of primary dysmenorrhea after starting to use oral contraceptives;
- Use of oral contraceptives for < 3 months prior to study selection;
- Use of an intrauterine device (IUD), hormonal implants or contraceptive injections in the last six (06) months;
- Previous diagnosis or physical examination findings and/or clinical and/or surgical history that may indicate the presence of endometriosis, pelvic inflammatory disease, adenomyosis, mullerian duct malformation, uterine fibroma, cystic ovary and/or pelvic varicocele;
Show all 27Show fewer
- History of recurrent pelvic and/or lower abdominal pain outside the menstrual period;
- Presence of known allergy or hypersensitivity to the components of the drugs used during the clinical trial;
- History of hypersensitivity reactions, such as asthma attacks or other types of allergic reactions, to acetylsalicylic acid or other NSAIDs;
- History or diagnosis of peptic/hemorrhagic ulcer;
- History of gastrointestinal bleeding or perforation related to the use of NSAIDs;
- Presence of compromised bone marrow function or diseases of the hematopoietic system;
- Diagnosis of acute intermittent hepatic porphyria;
- Diagnosis of congenital deficiency of glucose-6-phosphate dehydrogenase (G6PD);
- Diagnosis of untreated angle-closure glaucoma;
- Presence of mechanical stenosis in the gastrointestinal tract;
- Diagnosis of megacolon and/or paralytic or obstructive ileus;
- Diagnosis of myasthenia gravis;
- Treatment with psychoactive drugs (such as, for example, antidepressants, antipsychotics, etc.) in the 30 days prior to selection for the study;
- Participants with a history of alcohol or illicit drug use disorder in the last two (02) years;
- Participants with a current medical history of cancer and/or cancer treatment in the last five (05) years;
- Presence of any serious illness, at the discretion of the investigator;
- Any finding of clinical observation (clinical/physical evaluation) or laboratory condition that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical trial or presence of uncontrolled chronic disease(s);
- Participants who are pregnant, nursing or planning to become pregnant;
- Disagreement with the use of a known effective barrier contraceptive method, unless using a stable oral contraceptive for three months or more (which must be maintained throughout the study), or surgically sterile or who expressly declare themselves exempt from risk of pregnancy for not exercising sexual practices or exercising them in a non-reproductive manner;
- Participation in a clinical research protocol in the last 12 months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator judges that there may be a direct benefit to it;
- Presence of any condition that, at the discretion of the investigator, makes the patient unfit to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III, Crossover Study to Assess the Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
- Conditions
- Primary Dysmenorrhea
- Being tested
- CDE100 association, Buscopan® Composto association
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CDE100 associationDrug
Experimental drug.
Buscopan® Composto associationDrug
Active comparator.
| Study group | Role | What they receive |
|---|---|---|
| Experimental | Experimental | CDE100 The patient must take 1 pill of CDE100 association and placebo of Buscopan® Composto association, if pain, until three times a day. Receives: Drug: CDE100 association |
| Control | Active comparator | Buscopan® Composto association.
The patient must take 1 pill of Buscopan® Composto association and placebo of CDE100 association, if pain, until three times a day. Receives: Drug: Buscopan® Composto association |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose.
Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).
Measured: 4 hours post-dose.
Secondary outcomes (9)
Sum of Total Pain Relief (TOTPAR) over 0-8 hours post-dose.
Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-8 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).
Measured: 8 hours post-dose.
Sum of Pain Intensity Difference (SPID) over 4 hours post-dose.
Sum of Pain Intensity Difference (SPID) over 4 hours post-dose. The pain intensity will be assessed using a Categorical 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain).
Measured: 4 hours post-dose.
Sum of Pain Intensity Difference (SPID) over 8 hours post-dose.
Sum of Pain Intensity Difference (SPID) over 8 hours post-dose. The pain intensity will be assessed using a Categorical 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain).
Measured: 8 hours post-dose.
Time to first intake of rescue medication.
Time between the first dose intake and the administration of a rescue medication.
Measured: Up to 8 hours post-dose.
Patients who used rescue medication.
Number of participants who used rescue medication after the first drug intake.
Measured: Up to 8 hours post-dose.
Doses of rescue medication used.
Number of rescue medication doses used in the first day of treatment.
Measured: Up to 8 hours post-dose.
Number of additional drug intake.
Number of additional drug intake during the study period.
Measured: 3 days.
Patients' Global Impression of Change (PGIC).
Patients' Global Impression of Change (PGIC) will be assessed after 8 hours post-dose or immediately before the intake of rescue medication.
Measured: 8 hours.
Evaluate the safety of CDE100 association in the treatment of primary dysmenorrhea.
The safety will be evaluated considering the incidence of adverse events (AEs) reported during the study period.
Measured: Up to 175 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2022
- Study start11 Jun 2025
- Primary completion28 Jun 2026 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary DysmenorrheaStudies of the same condition, open and under way.
- More trials run by EMSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 238 participants (estimated)
Sponsor and investigators
- Lead sponsor
- EMS
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05640232
- Sponsor's protocol ID
- EMS0522 - ASTRAL
- Acronym
- ASTRAL
- Status last verified
- Dec 2025
- First submitted
- 29 Nov 2022
- Last updated
- 8 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A National, Multicenter, Randomized, Double-blind, Double-dummy, Phase III, Crossover Study to Assess the Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
- ClinicalTrials.gov ID
- NCT05640232
- Acronym / sponsor ID
- ASTRAL / EMS0522 - ASTRAL
- Conditions
- Primary Dysmenorrhea
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 238 participants (estimated)
- Lead sponsor
- EMSIndustry (pharma, biotech, devices)
- Study start
- 11 Jun 2025 (actual)
- Primary completion
- 28 Jun 2026 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 7 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental | Experimental | Drug: CDE100 associationCDE100 The patient must take 1 pill of CDE100 association and placebo of Buscopan® Composto association, if pain, until three times a day. |
| Control | Active comparator | Drug: Buscopan® Composto associationBuscopan® Composto association. The patient must take 1 pill of Buscopan® Composto association and placebo of CDE100 association, if pain, until three times a day. |
Who may qualify
- Ages
- 16 to 35 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (5 listed)
- Patient has given written informed consent to participate in the study prior to admission to the study;
- Female patients aged between 16 and 35 years old, inclusive;
- History of regular menstrual cycles, occuring between every 21 to 35 days;
- Clinical history compatible with the diagnosis of primary dysmenorrhea;
- Self-reported history of ≥ 4 painful cycles, with moderate or severe menstrual cramps, in the six (06) months prior to selection for the study.
Key exclusion criteria (27 listed)
- Diagnosis of secondary dysmenorrhea;
- History of non-response to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) to relieve menstrual cramps;
- Onset of primary dysmenorrhea after starting to use oral contraceptives;
- Use of oral contraceptives for < 3 months prior to study selection;
- Use of an intrauterine device (IUD), hormonal implants or contraceptive injections in the last six (06) months;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CDE100 associationExperimental drug. | Drug | Experimental |
| Buscopan® Composto associationActive comparator. | Drug | Control |
Primary outcome
Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose.
Time frame: 4 hours post-dose.
Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).
9 secondary outcomes
Sum of Total Pain Relief (TOTPAR) over 0-8 hours post-dose.
Time frame: 8 hours post-dose.
Sum of Pain Intensity Difference (SPID) over 4 hours post-dose.
Time frame: 4 hours post-dose.
Sum of Pain Intensity Difference (SPID) over 8 hours post-dose.
Time frame: 8 hours post-dose.
Time to first intake of rescue medication.
Time frame: Up to 8 hours post-dose.
Patients who used rescue medication.
Time frame: Up to 8 hours post-dose.
Doses of rescue medication used.
Time frame: Up to 8 hours post-dose.
Number of additional drug intake.
Time frame: 3 days.
Patients' Global Impression of Change (PGIC).
Time frame: 8 hours.
Evaluate the safety of CDE100 association in the treatment of primary dysmenorrhea.
Time frame: Up to 175 days.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Primary Dysmenorrhea
Not yet recruiting
Radiofrequency and Pelvic Floor Exercise for Primary Dysmenorrhea
Primary Dysmenorrhea
Not yet recruiting
Transcutaneous Cervical Vagus Nerve Stimulation for Primary Dysmenorrhea
Primary Dysmenorrhea (PD), Menstrual Pain
Recruiting
The Effect of Cognitive Exercise Therapy Approach and Yoga in Adolescents With Dysmenorrhoea
Dysmenorrhea, Primary Dysmenorrhea
Not yet recruiting
The Effect of Hydrogen-Rich Water on Dysmenorrhea and Menstrual Symptom Severity
Dysmenorrhea Primary
Not yet recruiting
Effect of Virtual Reality on Pain and Anxiety in Women With Dysmenorrhea
Primary Dysmenorrhea, Menstrual Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing CDE100 association and Buscopan® Composto association in people with Primary Dysmenorrhea, run by EMS at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alexandra F.D. Alves, MSc (+551938878917, pesquisa.clinica@ncfarma.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sum of Total Pain Relief (TOTPAR) over 0-4 hours post-dose. (time frame: 4 hours post-dose.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2025; AzTrials last refreshed its copy on 8 Nov 2026.